Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 3 trial of S-1 versus docetaxel in previously treated advanced non-small cell lung cancer
jRCT1080221121Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing S-1 arm with Docetaxel arm (2 arms). Primary endpoint: overall survival. Started Jun 2010; status: completed.
02
Drugs
tegafurdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080221121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221121.